Economic burden of influenza-like illness in long-term-care facilities

Carroll, NV; Delafuente, JC; McClure, KL; Weakley, DF; Khan, ZM; Cox, FM

doi:10.1093/ajhp/58.12.1133

Cited by 17 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prescription and OTC drug costs were analysed in 12 and 13 studies respectively. The mean prescription drug cost per episode ranges from US$1 in UK [ 36 ], Norway [ 25 ], and Korea [ 32 ], to US$ 60 in the US [ 14 ], whereas in Europe, the maximum identified cost per episode was found in Germany (US$16) [ 38 ]. The expected OTC expenditure per episode ranges between US$2 in Italy [ 26 ] and US$13 in Australia and Germany [ 16 , 37 ], and their impact varied between 2.8% and 18.6% of total health care costs and between 13.2% and 88.9% of total drug costs.…”

Section: Resultsmentioning

confidence: 99%

Health care costs of influenza-related episodes in high income countries: A systematic review

Federici¹,

Cavazza²,

Costa³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

IntroductionThis study systematically reviews costing studies of seasonal influenza-like illness (ILI) in high-income countries. Existing reviews on the economic impact of ILI do not report information on drug consumption and its costs, nor do they provide data on the overall cost per episode.MethodsThe PRISMA-P checklist was used to design the research protocol. Studies included were cost of illness analysis (COI) and modeling studies that estimated the cost of ILI episodes. Records were searched from January 2000 to December 2016 in electronic bibliographic databases including Medline, Embase, Science Direct, the Cochrane Library, the Centre for Reviews and Disseminations of the University of York, and Google scholar. References from the included studies were hand-searched for completion. Abstract screening, full-text analysis and data extraction were performed by two reviewers independently and discrepancies were resolved by discussion with a third reviewer. A standardized, pre-piloted form was used for data extraction. All costs were converted to 2015 US$ Purchasing Power Parities.ResultsThe literature search identified 5,104 records. After abstract and title screening, 76 studies were analyzed full-text and 27 studies were finally included in the review. Full estimates of the cost per episode range from US$19 in Korea to US$323 in Germany. Particularly, the cost per episode of laboratory confirmed influenza cases was estimated between US$64 and US$73. Inpatient and outpatient services account for the majority of the costs. Differences in the estimates may reflect country-specific characteristics, as well as other study-specific features including study design, identification strategy of ILI cases, study populations and types of costs included in the analysis. Children usually register higher costs, whereas evidence for the elderly is less conclusive. Patients risk-profile, co-morbidities and complications are the other important cost-drivers. None of the papers considered appropriateness in resource use (e.g. abuse of antibiotics). Despite cost of illness studies have ultimately a descriptive role, evidence on (in)appropriateness is useful for policy-makers.

show abstract

Section: Resultsmentioning

confidence: 99%

Health care costs of influenza-related episodes in high income countries: A systematic review

Federici¹,

Cavazza²,

Costa³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Costs were mainly driven by inpatient costs, which were 84% of total costs. 9 In Asia, published evidence on the economic burden of influenza is limited. In Australia, the estimated total direct influenza cost in people of all ages, in the absence of vaccination, was estimated at AU$115 million annually to the Australian health care system (AU$33.32 per consultation and between AU$5413 and AU$5986 per case of hospitalization).…”

Section: Background and Objectivesmentioning

confidence: 99%

Estimation of the Direct Cost of Treating People Aged More Than 60 Years Infected by Influenza Virus in Shanghai

Chen

et al. 2012

Asia Pac J Public Health

View full text Add to dashboard Cite

show abstract

“…14 Influenza and pneumococcal vaccinations are cost-effective and efficacious in containing disease in these settings. 5 The Advisory Committee on Immunization Practices recommends influenza vaccination for those living in LTCFs 6 and pneumococcal vaccination for patients in "certain social circumstances," which would include these residents for various reasons. 7 Immunization of all residents facilitates the benefits of herd immunity or protection for other residents in the facility.…”

mentioning

confidence: 99%

Characteristics of Long-Term–Care Facility Residents Associated With Receipt of Influenza and Pneumococcal Vaccinations

Bardenheier

Shefer

McKibben

et al. 2004

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

show abstract

Economic burden of influenza-like illness in long-term-care facilities

Cited by 17 publications

References 0 publications

Health care costs of influenza-related episodes in high income countries: A systematic review

Health care costs of influenza-related episodes in high income countries: A systematic review

Estimation of the Direct Cost of Treating People Aged More Than 60 Years Infected by Influenza Virus in Shanghai

Characteristics of Long-Term–Care Facility Residents Associated With Receipt of Influenza and Pneumococcal Vaccinations

Contact Info

Product

Resources

About